Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

Journal of Neuro-Oncology

Volumn 129, Issue 3, 2016, Pages 453-460

  Blumenthal, Deborah T ^a   Yalon, Michal ^b   Vainer, Gilad W ^a   Lossos, Alexander ^c   Yust, Shlomit ^d   Tzach, Lior ^b   Cagnano, Emanuela ^a   Limon, Dror ^d   Bokstein, Felix ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

Anti PD1; Glioblastoma; Immunotherapy; Pembrolizumab; Primary brain tumor

Indexed keywords

BEVACIZUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; STEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; BRAIN STEM TUMOR; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORD REVIEW; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; STEROID THERAPY; TUMOR GROWTH; TUMOR RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; COHORT ANALYSIS; DIAGNOSTIC IMAGING; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84976878200     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2190-1     Document Type: Article

References (39)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
3. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88
4. Bokstein F, Blumenthal DT, Corn BW et al (2016) Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. J Neurooncol 126:551–557
5. Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053
6. Cage TA, Samagh SP, Mueller S et al (2013) Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst 29:1313–1319
7. Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918
8. Zandberg DP, Strome SE (2014) The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 50:627–632
9. Tykodi SS (2014) PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 7:1349–1359
10. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
11. Herbst RS, Baas P, Kim DW et al (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550
12. Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023–1031
13. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
14. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
15. Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384
16. Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270–1271
17. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639
18. Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. doi:10.1016/S1470-2045(16)30066-3
19. Moskowitz CH, Ribrag V, Michot JM et al (2014) PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). In: 56th annual meeting of the American Society of Hematology, San Francisco, California
20. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034
21. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297
22. Zeng J, See AP, Phallen J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349
23. Sampson JH, Vlahovic G, Solmaz SS et al (2015) Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. J Clin Oncol 2015:33
24. Sampson JH, Vlahovic G, Desjardins A et al (2014) Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). J Clin Oncol 32:5
25. WM P (2001) Brain drug targeting: the future of brain drug development. Cambridge University Press, Cambridge
26. Cohen JV, Alomari AK, Vortmeyer AO et al (2016) Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res 4:179–182
27. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571
28. Nduom EK, Wei J, Yaghi NK et al (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18:195–205
29. Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421
30. Amayiri N, Tabori U, Campbell B et al (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138:380–385
31. Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211
32. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74
33. van Thuijl HF, Mazor T, Johnson BE et al (2015) Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol 129:597–607
34. Cahill DP, Levine KK, Betensky RA et al (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038–2045
35. Ngiow SF, McArthur GA, Smyth MJ (2015) Radiotherapy complements immune checkpoint blockade. Cancer Cell 27:437–438
36. Rothermundt C, Hader C, Gillessen S (2016) Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol 27:544–545
37. Berghoff AS, Kiesel B, Widhalm G et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17:1064–1075
38. Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL (2011) Principles of conservative prescribing. Arch Intern Med 171:1433–1440
39. Mackey TK, Schoenfeld VJ (2016) Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med 14:17